The new chief executive officer of Biogen Inc. aims to return the iconic biotech company to a path of sustainable growth after a rocky few years spent trying to replace shrinking sales of multiple sclerosis drugs.
Acquisitions aren’t off the table, Biogen CEO Chris Viehbacher said Monday at the JPMorgan Healthcare Conference in San Francisco, but his immediate priority for the first half of the year is “getting things right” inside Biogen. Viehbacher outlined ways the company could navigate its challenges, such as cutting more costs and looking outside its historical focus of neuroscience.
“I don’t see us getting into ...
